Welcome to our dedicated page for Solana Company news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana Company stock.
Solana Company (NASDAQ: HSDT) generates news across two distinct but connected areas: its neurotech medical device operations and its Solana-focused digital asset treasury strategy. Company press releases and SEC filings highlight developments in clinical research, regulatory submissions, capital markets transactions, and digital asset management.
On the medical device side, Solana Company describes itself as a neurotech company focused on neurologic deficits using an orally applied technology platform to promote neuroplasticity. News items include announcements of positive clinical data related to the PoNS® device and submissions to the U.S. Food and Drug Administration, such as a 510(k) filing for a stroke-related label expansion.
On the digital asset treasury side, Solana Company reports on its efforts to build and manage a treasury of Solana (SOL) tokens. Recent updates have covered a large private investment in public equity (PIPE) financing, the launch of an at-the-market (ATM) program, the approval of a stock repurchase plan, and partnerships with Pantera Capital and Summer Capital. The company also issues news about its SOL holdings, staking performance, and relationships with staking and custody providers, including Helius, Twinstake, Anchorage Digital Bank, and BitGo.
Investors following HSDT news can expect coverage of quarterly financial results, changes in auditors and board composition, applications affecting its reporting status in Canada, and initiatives such as the planned tokenization of HSDT shares on Superstate’s Opening Bell platform. This news page aggregates these disclosures so readers can review Solana Company’s operational, financial, and treasury-related updates in one place.
Helius Medical Technologies (Nasdaq:HSDT) has launched a new website to enhance resources for U.S.-based patients and physicians regarding its PoNS Treatment. As part of its pre-commercial activities, the company aims to raise awareness and educate key clinicians about the PoNS device, which is designed for treating gait deficits associated with multiple sclerosis. The device is expected to be commercialized in Q1 2022. The company faces several challenges, including securing Medicare coverage and building a commercial infrastructure.
Helius Medical Technologies (Nasdaq:HSDT) announced its upcoming participation in two virtual investor conferences in July 2021. The first is the Ladenburg Thalmann Healthcare Conference, where management will present on July 14 at 11:30 a.m. Eastern Time. The second is the Alliance Global Partners Virtual MedTech Summer Conference, where management will engage in virtual 1x1 meetings on July 29. A webcast of the presentation will be available on their investor relations website for replay after the conference.
Helius Medical Technologies (Nasdaq:HSDT) announced the appointment of Dr. Antonella Favit-Van Pelt as Chief Medical Officer. Dr. Favit-Van Pelt brings over 20 years of experience in neurology and medical program leadership. Her expertise will support the advancement of PoNS technology, highlighted by recent U.S. regulatory clearance for treating multiple sclerosis. As part of her induction, she received options for 18,000 shares, priced at $16.45 with a four-year vesting schedule. Helius aims to enhance awareness and expand its clinical and regulatory strategies under her leadership.
Helius Medical Technologies has announced its participation in the Annual World Congress of the Society for Brain Mapping and Therapeutics from July 8-11, 2021, in Los Angeles. The company will receive the Pioneer in Technology Award, recognizing its innovative contributions to neurotechnology. Co-Founder Dr. Jonathan Sackier will present on the PoNS™ device, highlighting its role in treating gait deficits associated with conditions like multiple sclerosis. This non-surgical device delivers electrical stimulation through the tongue, showing promise in enhancing neurological wellness.
Helius Medical Technologies (NASDAQ:HSDT) announced that it will release its second quarter fiscal year 2021 financial results on August 12, 2021, after market close. Management will host a conference call at 5:00 p.m. ET to discuss the results, accessible via phone and a live webcast. The PoNS™ device is currently authorized for treatment of gait deficit from multiple sclerosis in the U.S. and is available for similar conditions in Canada. For more details, visit the company's investor relations website.
Helius Medical Technologies, Inc. (Nasdaq:HSDT) announced the appointment of Dane C. Andreeff as President and CEO and Jeffrey S. Mathiesen as CFO, effective June 14, 2021. Andreeff has served as Interim CEO since August 2020 and Mathiesen has experience in CFO roles across technology-based companies for nearly 30 years. The board expressed confidence in their leadership capabilities to guide Helius through a critical growth phase, focusing on the PoNS™ technology aimed at improving disabilities related to multiple sclerosis.
Helius Medical Technologies, a neurotech company, will participate in Noble Capital Markets’ Virtual Road Show Series on June 10, 2021. The event will feature a corporate presentation followed by a Q&A session led by Senior Research Analyst Joe Gomes. Interested parties can register for the live webcast at 1:00 p.m. Eastern Time, and a recording will be available afterwards. Helius is focused on developing non-invasive technologies that enhance neurological wellness, including the Portable Neuromodulation Stimulator (PoNS), aimed at treating gait deficits from conditions like multiple sclerosis.
Helius Medical Technologies (Nasdaq:HSDT) announced the appointment of Frederick Fantazzia as Vice President of Sales & Marketing for North America, effective June 1, 2021. Fantazzia brings 16 years of experience in the neuromodulation field, previously serving at LivaNova. He aims to develop the market for Helius’s PoNS Treatment, authorized for sale in the U.S. for multiple sclerosis patients experiencing gait deficit. This leadership change comes as the company prepares for commercialization efforts.
Helius Medical Technologies (Nasdaq:HSDT) reported Q1 2021 results showing a net loss of $3.4 million, down from $4.8 million a year prior. Revenue was $84,000 compared to $207,000 in the same quarter last year. The company received FDA marketing authorization for its Portable Neuromodulation Stimulator (PoNS™) for treating gait deficits in MS patients. Cash reserves increased to $11.4 million, up from $3.3 million at year-end 2020. Helius aims to commercialize PoNS in the U.S. in Q1 2022, while addressing reimbursement strategies following recent CMS announcements.
Helius Medical Technologies (Nasdaq:HSDT) announced participation in the Planet MicroCap Showcase from April 20-22, 2021. Management will present on April 21 at 8:30 a.m. ET. A live audio webcast of the presentation will be accessible on the investor relations website under the 'Events' section. Helius is a neurotech company dedicated to promoting neurological wellness through innovative technologies like the Portable Neuromodulation Stimulator (PoNS™), which aids in treating gait deficits due to multiple sclerosis. More details are available on their official website.